SPY425.10+2.50 0.59%
DIA341.98+3.20 0.94%
IXIC14,369.71+97.98 0.69%

HC Wainwright & Co. Maintains Buy on Mirati Therapeutics, Lowers Price Target to $251

HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $255 to $251.

05/10/2021 06:13
HC Wainwright & Co. analyst Edward White maintains Mirati Therapeutics (NASDAQ:MRTX) with a Buy and lowers the price target from $255 to $251.